Skip to Content
Merck
  • Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen.

Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen.

Stem cell research (2016-04-12)
Arnaud Carpentier, Ila Nimgaonkar, Virginia Chu, Yuchen Xia, Zongyi Hu, T Jake Liang
ABSTRACT

The establishment of protocols to differentiate human pluripotent stem cells (hPSCs) including embryonic (ESC) and induced pluripotent (iPSC) stem cells into functional hepatocyte-like cells (HLCs) creates new opportunities to study liver metabolism, genetic diseases and infection of hepatotropic viruses (hepatitis B and C viruses) in the context of specific genetic background. While supporting efficient differentiation to HLCs, the published protocols are limited in terms of differentiation into fully mature hepatocytes and in a smaller-well format. This limitation handicaps the application of these cells to high-throughput assays. Here we describe a protocol allowing efficient and consistent hepatic differentiation of hPSCs in 384-well plates into functional hepatocyte-like cells, which remain differentiated for more than 3weeks. This protocol affords the unique opportunity to miniaturize the hPSC-based differentiation technology and facilitates screening for molecules in modulating liver differentiation, metabolism, genetic network, and response to infection or other external stimuli.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-α-Fetoprotein (AFP) antibody produced in mouse, ascites fluid, clone C3
Sigma-Aldrich
Anti-CYP2D6 antibody produced in rabbit, IgG fraction of antiserum